Compare Newmont Corporation (NEM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Tango Therapeutics Inc. — how do they compare? Newmont Corporation trades at $111.93 (market cap $121.80B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Newmont Corporation is far larger — about 32.5× Tango Therapeutics Inc.'s market cap, and Newmont Corporation pays a 0.9% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 59 Days and Tango Therapeutics Inc. for 0 Days on average.
| NEM | TNGX | |
|---|---|---|
Market Cap | $121.80B | $3.75B |
Volume | 4,383,120 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $32.90 |
52-Week Low | $78.63 | $7.50 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $118.39B | $2.77B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $111.56, down 4.77% over the past 24 hours, with strong fundamental performance including record free cash flow of $5.3 billion in H1 2026 and three consecutive quarterly earnings beats. The stock shows a bullish technical signal with moving averages supporting upward momentum, while maintaining attractive valuation metrics including a P/E of 14.58 and EV/EBITDA of 7.38. Recent news highlights the company's focus on per-share growth and operational improvements amid constructive gold market conditions.
Newmont presents a compelling investment case with robust profitability (33.36% net margin), strong analyst consensus (76% buy ratings), and 22% upside to the $136.83 price target. Key risks include gold price volatility and execution of growth initiatives, but the company's record cash flow generation and improving balance sheet provide solid foundation for continued shareholder value creation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
